CN113164589A - 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 - Google Patents

用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 Download PDF

Info

Publication number
CN113164589A
CN113164589A CN201980056952.6A CN201980056952A CN113164589A CN 113164589 A CN113164589 A CN 113164589A CN 201980056952 A CN201980056952 A CN 201980056952A CN 113164589 A CN113164589 A CN 113164589A
Authority
CN
China
Prior art keywords
macrophages
monocytes
agent
activity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056952.6A
Other languages
English (en)
Chinese (zh)
Inventor
T·I·诺沃布兰塞瓦
I·费尔德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viseo Pharmaceutical Co
Original Assignee
Viseo Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viseo Pharmaceutical Co filed Critical Viseo Pharmaceutical Co
Publication of CN113164589A publication Critical patent/CN113164589A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN201980056952.6A 2018-06-29 2019-06-28 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 Pending CN113164589A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692463P 2018-06-29 2018-06-29
US62/692463 2018-06-29
US201962810683P 2019-02-26 2019-02-26
US62/810683 2019-02-26
US201962857199P 2019-06-04 2019-06-04
US62/857199 2019-06-04
US201962867532P 2019-06-27 2019-06-27
US62/867532 2019-06-27
PCT/US2019/039773 WO2020006385A2 (en) 2018-06-29 2019-06-28 Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof

Publications (1)

Publication Number Publication Date
CN113164589A true CN113164589A (zh) 2021-07-23

Family

ID=68985243

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056952.6A Pending CN113164589A (zh) 2018-06-29 2019-06-28 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途

Country Status (10)

Country Link
US (1) US20210189342A1 (https=)
EP (1) EP3813881A4 (https=)
JP (1) JP2021529753A (https=)
KR (1) KR20210040948A (https=)
CN (1) CN113164589A (https=)
AU (1) AU2019293600A1 (https=)
BR (1) BR112020026386A2 (https=)
CA (1) CA3103154A1 (https=)
TW (1) TW202023629A (https=)
WO (1) WO2020006385A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113897397A (zh) * 2021-09-30 2022-01-07 中南大学 一种基于DNAzyme调控基因编辑的方法
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN114010666A (zh) * 2021-10-22 2022-02-08 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN114214237A (zh) * 2021-12-23 2022-03-22 南京大学 一种洗脱细胞表面吸附纳米颗粒的方法
CN115029473A (zh) * 2022-06-21 2022-09-09 湖北省药品监督检验研究院 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法
CN115443141A (zh) * 2019-12-30 2022-12-06 联邦高等教育系统匹兹堡大学 胰腺内巨噬细胞m2极化治疗1型糖尿病
CN116403649A (zh) * 2023-03-17 2023-07-07 中山大学附属第六医院 一种igsf6基因在免疫治疗治疗系统中的应用
TWI873056B (zh) * 2024-07-01 2025-02-11 國立成功大學 採用影像分割技術的胃內視鏡影像分析方法與電腦系統

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3866818B1 (en) * 2018-10-19 2025-07-23 Regenics AS Use of fish egg cellular extractt for wound healing
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20220042128A (ko) * 2019-06-27 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
CA3142838A1 (en) * 2019-06-27 2020-12-30 Verseau Therapeutics, Inc. Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US11987612B2 (en) 2019-11-04 2024-05-21 Alector Llc Siglec-9 ECD fusion molecules
WO2021154709A1 (en) * 2020-01-28 2021-08-05 Nanotomer, Inc. Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo
US11642629B2 (en) * 2020-03-20 2023-05-09 Saudi Arabian Oil Company Multi-layer composite gas separation membranes, methods for preparation, and use
CN115667544A (zh) * 2020-03-27 2023-01-31 无界生物公司 鉴定染色体外dna特征的方法
JP7560893B2 (ja) 2020-04-20 2024-10-03 デュオジェニック ステムセルズ コーポレーション 修飾マクロファージ、組成物およびその使用
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
CN112837306B (zh) * 2021-02-20 2022-11-22 薛竟宜 基于深度学习和中智理论的冠状动脉病变功能学定量方法
CN113884682B (zh) * 2021-04-30 2023-07-21 中国医学科学院血液病医院(中国医学科学院血液学研究所) 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途
WO2023004235A1 (en) * 2021-07-23 2023-01-26 University Of Florida Research Foundation, Incorporated Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design
CN115739182B (zh) * 2022-11-17 2024-01-16 合肥机数量子科技有限公司 含单分散铁原子的过氧化物模拟酶及其制备方法和用途
WO2024189098A1 (en) * 2023-03-13 2024-09-19 Iomx Therapeutics Ag Platform technology for the identification of modulators of immune effector cell function
AU2024237943A1 (en) * 2023-03-20 2025-10-09 The Regents Of The University Of California Methods and materials for treating cancer
CN117159495A (zh) * 2023-08-16 2023-12-05 北京大学 脂质纳米颗粒及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285812A1 (en) * 2008-05-15 2009-11-19 Richard Alvarez Anti-psgl-1 antibodies and methods of identification and use
US20140255417A1 (en) * 2011-10-21 2014-09-11 Transgene Sa Modulation of macrophage activation
US20160279286A1 (en) * 2013-11-20 2016-09-29 Drexel University Compositions and methods for macrophage conversion
WO2018002640A2 (en) * 2016-07-01 2018-01-04 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972703A (zh) * 2004-03-30 2007-05-30 丹麦皇家兽医和农业学院 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US20170306042A1 (en) * 2014-08-29 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3568159A4 (en) * 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285812A1 (en) * 2008-05-15 2009-11-19 Richard Alvarez Anti-psgl-1 antibodies and methods of identification and use
US20110081666A1 (en) * 2008-05-15 2011-04-07 Richard Alvarez Anti-psgl-1 inhibitors and screening methods
US20140255417A1 (en) * 2011-10-21 2014-09-11 Transgene Sa Modulation of macrophage activation
US20160279286A1 (en) * 2013-11-20 2016-09-29 Drexel University Compositions and methods for macrophage conversion
WO2018002640A2 (en) * 2016-07-01 2018-01-04 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JIALIN LI等: "VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism", NAT COMMUN, vol. 8, no. 1, pages 1322, XP055896128, DOI: 10.1038/s41467-017-01327-4 *
JUNG MI BYUN等: "The Significance of VSIG4 Expression in Ovarian Cancer", INT J GYNECOL CANCER, vol. 27, no. 5, pages 872 - 878, XP055896492, DOI: 10.1097/IGC.0000000000000979 *
NORMAN NUÑEZ-ANDRADE等: "P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria", J PATHOL, vol. 224, no. 2, 22 March 2011 (2011-03-22), pages 214 *
Y ZHENG等: "PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma", LEUKEMIA, vol. 27, no. 3, pages 702 - 710, XP037786088, DOI: 10.1038/leu.2012.272 *
YAN LI等: "Costimulatory molecule VSIG4 exclusively expressed on macrophages alleviates renal tubulointerstitial injury in VSIG4 KO mice", J NEPHROL, vol. 27, no. 1, pages 29 - 36, XP009532861, DOI: 10.1007/s40620-013-0022-3 *
YUNMEI LIAO等: "VSIG4 expression on macrophages facilitates lung cancer development", LAB INVEST, vol. 94, no. 7, pages 706 - 715, XP055357214, DOI: 10.1038/labinvest.2014.73 *
徐保平等: "巨噬细胞极化在脊髓损伤中的作用机制", 中国骨伤, vol. 31, no. 1, 31 January 2018 (2018-01-31), pages 89 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443141A (zh) * 2019-12-30 2022-12-06 联邦高等教育系统匹兹堡大学 胰腺内巨噬细胞m2极化治疗1型糖尿病
CN113897397A (zh) * 2021-09-30 2022-01-07 中南大学 一种基于DNAzyme调控基因编辑的方法
CN113897397B (zh) * 2021-09-30 2024-04-02 中南大学 一种基于DNAzyme调控基因编辑的方法
CN114010666A (zh) * 2021-10-22 2022-02-08 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN114214237A (zh) * 2021-12-23 2022-03-22 南京大学 一种洗脱细胞表面吸附纳米颗粒的方法
CN115029473A (zh) * 2022-06-21 2022-09-09 湖北省药品监督检验研究院 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法
CN116403649A (zh) * 2023-03-17 2023-07-07 中山大学附属第六医院 一种igsf6基因在免疫治疗治疗系统中的应用
TWI873056B (zh) * 2024-07-01 2025-02-11 國立成功大學 採用影像分割技術的胃內視鏡影像分析方法與電腦系統

Also Published As

Publication number Publication date
TW202023629A (zh) 2020-07-01
US20210189342A1 (en) 2021-06-24
EP3813881A2 (en) 2021-05-05
WO2020006385A2 (en) 2020-01-02
EP3813881A4 (en) 2022-09-14
WO2020006385A3 (en) 2020-02-13
JP2021529753A (ja) 2021-11-04
CA3103154A1 (en) 2020-01-02
BR112020026386A2 (pt) 2021-03-30
AU2019293600A1 (en) 2021-01-14
KR20210040948A (ko) 2021-04-14

Similar Documents

Publication Publication Date Title
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
US11660341B2 (en) mRNA combination therapy for the treatment of cancer
RU2768829C2 (ru) Противораковые рнк-вакцины
EP3888674B1 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
KR20220104217A (ko) Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
TW202016139A (zh) Bcma 嵌合抗原受體及其用途
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
KR20200046065A (ko) 암을 치료하기 위한 병용 면역 요법 및 사이토카인 조절 요법
CN114401991A (zh) 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
US20210317461A1 (en) Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN114401990A (zh) 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
CN115996953A (zh) 用于调节髓系细胞炎性表型的抗vsig4组合物和方法及其用途
CN114728057A (zh) 用于调节髓系细胞炎性表型的抗cd53组合物和方法及其用途
KR20250017231A (ko) 면역 반응을 조절하기 위한 조성물 및 방법
TW202333802A (zh) 用於肺癌之治療性rna(二)
CN114423452A (zh) 用于调节髓系细胞炎性表型的抗lrrc25组合物和方法及其用途
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
TW202346576A (zh) 治療性t細胞產品
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
WO2024215711A1 (en) Modified mammalian vesicles and compositions and methods related thereto
WO2023235479A1 (en) Compositions and methods for treating cancer
HK40056916B (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
BR122023022573A2 (pt) Moléculas de ácido nucleico isoladas, receptores de antígeno quimérico de bcma e usos dos mesmos, moléculas de polipeptídeo isoladas, domínios de ligação anti-bcma, vetores, células e métodos de produção das mesmas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination